Dianthus Therapeutics, Inc.
DNTH
$43.97
$1.694.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.24% | -7.18% | -3.77% | -12.97% | -42.98% |
| Total Depreciation and Amortization | 0.00% | -25.56% | 70.51% | -32.76% | 4.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -29.00% | 34.45% | 154.55% | 12.42% | -55.51% |
| Change in Net Operating Assets | -6.45% | 283.52% | -294.08% | -116.24% | 799.31% |
| Cash from Operations | -27.89% | 13.53% | -0.68% | -29.04% | -46.39% |
| Capital Expenditure | 89.13% | -91.67% | 22.58% | -24.00% | -47.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -859.77% | 78.78% | 164.21% | 91.10% | -21,966.69% |
| Cash from Investing | -861.11% | 78.75% | 164.02% | 91.09% | -22,286.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 48,260.04% | 252.80% | -99.59% | 13,304.05% | 529.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 48,229.75% | 252.80% | -99.59% | 13,304.05% | 113.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,267.61% | 124.62% | -16.52% | 96.12% | -1,702.22% |